Physician profile
Michael Gerhardt
NPI 1003905191
$327,990.61
in general payments reported to CMS, 2019-2025
26 companies · $42K in 2025
The $42K reported for 2025 was more than what 94% of Sports Medicine (Orthopaedic Surgery) providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $41K · 2021: $23K · 2022: $54K · 2023: $51K · 2024: $54K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $123K · Food and Beverage: $11K · Royalty Or License: $7,067 · Travel and Lodging: $4,367 · Consulting Fee: $1,200 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122,846.65 |
| Food and Beverage | $10,684.64 |
| Royalty Or License | $7,066.94 |
| Travel and Lodging | $4,366.75 |
| Consulting Fee | $1,200.00 |
| Education | $101.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $266,542.07 | 2019-2025 | Arthrex, Knee & Hip Instruments Hip Instruments |
| Medacta USA, INC. | $21,754.73 | 2019-2025 | Mecta |
| Exactech, INC. | $14,571.76 | 2019 | |
| Medical Device Business Services, INC. | $9,487.63 | 2019-2023 | Actis |
| Smith+Nephew, INC. | $7,175.90 | 2019-2025 | N/A, Q-Fix, Cap-Fix |
| Stryker Corporation | $3,444.75 | 2019-2025 | Mako, Triathlon, Insignia |
| Saxum Surgical, INC. | $1,226.39 | 2022 | |
| Depuy Synthes Sales INC. | $1,162.48 | 2019-2025 | Truespan Orthocord, Dynatape, Na |
| Bioventus LLC | $647.65 | 2019-2024 | Durolane, Durolane, L360 Thigh System |
| Ossio INC | $599.22 | 2023-2024 | |
| Nextstep Arthropedix, LLC | $442.78 | 2019-2022 | |
| Ossur Americas, INC. | $142.22 | 2024 | Miami J |
| Siemens Medical Solutions USA, INC. | $120.33 | 2021 | |
| Micromed INC | $100.86 | 2020 | |
| Episurf Medical, INC. | $84.54 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $77.00 | 2019 | |
| Medtronic, INC. | $70.40 | 2024 | Aquamantys(Tm) |
| Avanos Medical | $67.91 | 2019-2022 | |
| Innovation Technologies INC | $62.50 | 2021 | |
| Seapearl East, INC | $46.82 | 2023 | |
| Pacira Therapeutics, INC. | $41.03 | 2019-2021 | |
| Linvatec Corporation | $30.19 | 2024 | Biobrace 23mm |
| Ethicon US, LLC | $29.38 | 2019 | |
| Heron Therapeutics, INC. | $24.13 | 2022 | |
| Orthofix Medical, INC. | $19.27 | 2022 | |
| Vericel Corporation | $18.67 | 2025 | Maci |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gerhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.